Question · asked by 1 review
Liposomal daunorubicin vs ABV: Clinical response ‐ stable disease
- Population
- HIV‐infected adults with severe (T1) Kaposi's sarcoma
- Intervention
- Liposomal daunorubicin
- Comparison
- ABV
- Outcome
- Clinical response ‐ stable disease
Liposomal daunorubicin showed no clear difference in clinical response ‐ stable disease compared with ABV (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Liposomal daunorubicin vs ABV Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Liposomal daunorubicin showed no clear difference in clinical response ‐ stable disease compared with ABV (moderate certainty). Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane Headline outcomes only | RR 1.08 [0.87, 1.33] | 1 study · 227 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.